BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025, at 6:00 p.m. ET.

Link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at www.biocryst.com.

About BioCryst PharmaceuticalsBioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:John Bluth+1 919 859 7910jbluth@biocryst.com

BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more BioCryst Pharmaceuticals Charts.
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more BioCryst Pharmaceuticals Charts.